Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California 94158, USA; email:
Annu Rev Biochem. 2019 Jun 20;88:365-381. doi: 10.1146/annurev-biochem-061516-044805. Epub 2019 Jan 11.
Covalent inhibitors are widely used in drug discovery and chemical biology. Although covalent inhibitors are frequently designed to react with noncatalytic cysteines, many ligand binding sites lack an accessible cysteine. Here, we review recent advances in the chemical biology of lysine-targeted covalent inhibitors and chemoproteomic probes. By analyzing crystal structures of proteins bound to common metabolites and enzyme cofactors, we identify a large set of mostly unexplored lysines that are potentially targetable with covalent inhibitors. In addition, we describe mass spectrometry-based approaches for determining proteome-wide lysine ligandability and lysine-reactive chemoproteomic probes for assessing drug-target engagement. Finally, we discuss the design of amine-reactive inhibitors that form reversible covalent bonds with their protein targets.
共价抑制剂在药物发现和化学生物学中得到了广泛的应用。尽管共价抑制剂通常被设计成与非催化性半胱氨酸反应,但许多配体结合位点缺乏可及的半胱氨酸。在这里,我们综述了赖氨酸靶向共价抑制剂和化学蛋白质组学探针的化学生物学方面的最新进展。通过分析与常见代谢物和酶辅因子结合的蛋白质的晶体结构,我们确定了一组很大的、大部分未被探索的赖氨酸,这些赖氨酸可能可以用共价抑制剂进行靶向治疗。此外,我们还描述了基于质谱的方法来确定全蛋白质组的赖氨酸配体能力,以及用于评估药物靶标结合的赖氨酸反应性化学蛋白质组学探针。最后,我们讨论了设计与蛋白质靶标形成可逆共价键的胺反应抑制剂。